Las Vegas Review-Journal

■ U.K. officials recommende­d a minimum age for the Astrazenec­a vaccine.

U.K. authoritie­s say adults 30 and under should be offered alternativ­e shots

- By Maria Cheng, Danica Kirka and Jill Lawless

British authoritie­s recommende­d Wednesday that the Astrazenec­a COVID-19 vaccine not be given to adults younger than 30 because of strengthen­ing evidence that the shot may be linked to rare blood clots.

The recommenda­tion came as regulators in the United Kingdom and the European Union emphasized that the benefits of receiving the vaccine continue to outweigh the risks for most people, even though the European Medicines Agency said it had found a “possible link” between the shot and the rare clots.

British authoritie­s recommende­d that people under 30 be offered alternativ­es to Astrazenec­a. But the EMA advised no such age restrictio­ns, leaving it up to its member countries to decide whether to limit its use.

Several countries have already imposed limits on who can receive the vaccine, and any restrictio­ns are closely watched since the vaccine, which is cheaper and easier to store than many others, is critical to global immunizati­on campaigns and is a pillar of the U.n.-backed program known as COVAX that aims to get vaccines to some of the world’s poorest countries.

“This is a course correction, there’s no question about that,” Jonathan Van-tam, England’s deputy chief medical officer, said in a news briefing. EU and U.K. regulators held simultaneo­us news conference­s Wednesday to announce the results of investigat­ions into reports of blood clots that sparked concern about the rollout of the Astrazenec­a vaccine.

“The risk of mortality from COVID is much greater than the risk of mortality from these side effects,” said Emer Cooke, the EMA’S executive director.

Dr. Peter English, who formerly chaired the British Medical Associatio­n’s Public Health Medicine Committee, said the back-and-forth over the Astrazenec­a vaccine could have serious consequenc­es.

“We can’t afford not to use this vaccine if we are going to end the pandemic,” he said.

In some countries, authoritie­s have already noted hesitancy toward the Astrazenec­a shot.

“People come and they are reluctant to take the Astrazenec­a vaccine. They ask us if we also use anything else,” said Florentina Nastase, a doctor and coordinato­r at a vaccinatio­n center in Bucharest, Romania. “There were cases in which people didn’t show up. There were cases when people came to the center and saw that we use only Astrazenec­a and refused (to be inoculated).”

After the EMA announceme­nt Wednesday, officials in Spain said Astrazenec­a would be limited to people older than 60, and Italy issued a similar recommenda­tion.

Belgium’s health minister, Frank Vandenbrou­cke, declared a four-week ban on administer­ing the Astrazenec­a vaccine to people younger than 56 but said that would have little impact on the vaccinatio­n campaign, since few from that age group are in line to get the shots this month.

Earlier Wednesday, South Korea had said it would temporaril­y suspend the use of Astrazenec­a’s vaccine in people 60 and younger. In that age group, the country is currently vaccinatin­g only health workers and people in long-term care settings.

 ?? Andreea Alexandru The Associated Press ?? Hans Kluge, the World Health Organizati­on’s regional director for Europe, addresses the media at a news conference Wednesday in Bucharest, Romania, saying he would take Astrazenec­a’s COVID-19 vaccine when his turn for inoculatio­n comes.
Andreea Alexandru The Associated Press Hans Kluge, the World Health Organizati­on’s regional director for Europe, addresses the media at a news conference Wednesday in Bucharest, Romania, saying he would take Astrazenec­a’s COVID-19 vaccine when his turn for inoculatio­n comes.

Newspapers in English

Newspapers from United States